Cowen analyst Ritu Baral reiterated an Outperform rating on Aptinyx (NASDAQ: APTX), following the company's readout of Phase 2b trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE